Shenzhen Salubris Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Shenzhen Salubris Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.2% per year. Shenzhen Salubris Pharmaceuticals's return on equity is 7.1%, and it has net margins of 15.6%.
Key information
6.8%
Earnings growth rate
5.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.2% |
| Return on equity | 7.1% |
| Net Margin | 15.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shenzhen Salubris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,910 | 611 | 1,673 | 459 |
| 30 Jun 24 | 3,724 | 587 | 1,530 | 447 |
| 31 Mar 24 | 3,569 | 569 | 1,415 | 439 |
| 31 Dec 23 | 3,365 | 580 | 1,305 | 409 |
| 30 Sep 23 | 3,390 | 577 | 1,224 | 432 |
| 30 Jun 23 | 3,498 | 627 | 1,271 | 453 |
| 31 Mar 23 | 3,434 | 611 | 1,278 | 516 |
| 01 Jan 23 | 3,482 | 637 | 1,335 | 534 |
| 30 Sep 22 | 3,419 | 681 | 1,474 | 502 |
| 30 Jun 22 | 3,350 | 645 | 1,499 | 475 |
| 31 Mar 22 | 3,228 | 616 | 1,461 | 378 |
| 01 Jan 22 | 3,058 | 534 | 1,340 | 357 |
| 30 Sep 21 | 2,792 | 185 | 1,192 | 318 |
| 30 Jun 21 | 2,579 | 101 | 1,095 | 324 |
| 31 Mar 21 | 2,638 | 66 | 1,062 | 369 |
| 31 Dec 20 | 2,739 | 61 | 1,179 | 371 |
| 30 Sep 20 | 3,041 | 266 | 1,390 | 436 |
| 30 Jun 20 | 3,650 | 279 | 1,603 | 706 |
| 31 Mar 20 | 4,148 | 544 | 1,809 | 721 |
| 31 Dec 19 | 4,470 | 715 | 1,855 | 763 |
| 30 Sep 19 | 4,681 | 1,025 | 1,739 | 703 |
| 30 Jun 19 | 4,741 | 1,301 | 1,775 | 454 |
| 31 Mar 19 | 4,714 | 1,364 | 1,683 | 435 |
| 31 Dec 18 | 4,652 | 1,458 | 1,578 | 407 |
| 30 Sep 18 | 4,587 | 1,508 | 1,580 | 401 |
| 30 Jun 18 | 4,386 | 1,511 | 1,285 | 513 |
| 31 Mar 18 | 4,308 | 1,491 | 1,344 | 419 |
| 31 Dec 17 | 4,154 | 1,452 | 1,336 | 327 |
| 30 Sep 17 | 4,106 | 1,451 | 1,311 | 225 |
| 30 Jun 17 | 3,976 | 1,432 | 1,386 | 0 |
| 31 Mar 17 | 3,891 | 1,415 | 1,266 | 0 |
| 31 Dec 16 | 3,833 | 1,396 | 1,216 | 0 |
| 30 Sep 16 | 3,739 | 1,380 | 1,141 | 0 |
| 30 Jun 16 | 3,711 | 1,341 | 1,153 | 0 |
| 31 Mar 16 | 3,610 | 1,310 | 1,103 | 0 |
| 31 Dec 15 | 3,478 | 1,266 | 1,058 | 0 |
| 30 Sep 15 | 3,467 | 1,217 | 1,038 | 0 |
| 30 Jun 15 | 3,237 | 1,166 | 966 | 0 |
| 31 Mar 15 | 3,015 | 1,102 | 926 | 0 |
| 31 Dec 14 | 2,883 | 1,042 | 902 | 0 |
| 30 Sep 14 | 2,686 | 989 | 866 | 0 |
| 30 Jun 14 | 2,570 | 933 | 840 | 0 |
| 31 Mar 14 | 2,450 | 883 | 813 | 0 |
| 31 Dec 13 | 2,327 | 830 | 775 | 0 |
Quality Earnings: 002294 has high quality earnings.
Growing Profit Margin: 002294's current net profit margins (15.6%) are lower than last year (17%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002294's earnings have grown by 6.8% per year over the past 5 years.
Accelerating Growth: 002294's earnings growth over the past year (5.9%) is below its 5-year average (6.8% per year).
Earnings vs Industry: 002294 earnings growth over the past year (5.9%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 002294's Return on Equity (7.1%) is considered low.